Drug intelligence / Profile preview

DIOS-HFVac3

Development stage: Preclinical
Lead developer: DIOSynVax
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular, Subcutaneous

Overview

DIOS-HFVac3 is a vaccine candidate developed by DIOSynVax designed to provide protection against viral hemorrhagic fevers. The vaccine is built using DIOSynVax's proprietary Vaccine Antigen Payloads (VAPs) platform, which employs synthetic biology and computational design to create optimized antigens. This technology is intended to elicit broadly protective immune responses by targeting conserved regions of viral pathogens, potentially offering protection across multiple strains or related species. As of early 2024, the candidate was reported to be in the manufacturing stage following preclinical development.

Beyond the preview

Go deeper on DIOS-HFVac3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DIOS-HFVac3.

Explore the full profile